Iloperidone - Vanda Pharmaceuticals

Drug Profile

Iloperidone - Vanda Pharmaceuticals

Alternative Names: Fanapt; Fanaptum; Fiapta; HP 873; ILO 522; Zomaril

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer MegaPharm Ltd; Novartis; PROBIOMED; University of Colorado at Denver; Vanda Pharmaceuticals
  • Class Antipsychotics; Isoxazoles; Piperidines; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Schizophrenia
  • Phase II Post-traumatic stress disorders

Most Recent Events

  • 13 Apr 2018 Vanda Pharmaceuticals wins patent infringement appeal case against West Ward Pharmaceuticals
  • 09 Nov 2017 The European Medicines Agency refuses grant of Marketing authorisation for iloperidone for Schizophrenia
  • 07 Nov 2017 Federal Circuit Court of Appeals accepts patent dispute filed against West-Ward Pharmaceutical by Vanda Pharmaceuticals for ANDA product infringing the US patent number 8 586 610 of tasimelteon in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top